Dreavent Capital - aVenture Asset Manager Research
Dreavent Capital
Operating Status: Operating
Dreavent Capital: A Cambridge-based financial firm investing in Biotech Therapeutics.
Location
Cambridge, MA, US
Founded
2020
Dreavent Capital is a Cambridge-based investment firm specializing in Biotech Therapeutics. The firm primarily invests in Series A and Series B rounds, supporting early to mid-stage companies in the biotechnology sector. Dreavent Capital focuses on nurturing innovative therapeutic solutions, contributing significant capital to help these companies advance their research and development efforts.
Notable portfolio companies include Aardvark Therapeutics, Astrocyte Pharmaceuticals, Inspirna, and Nido Biosciences, with investments ranging from $6 million to $18.4 million. Dreavent Capital's key decision-makers bring extensive industry experience and a deep understanding of biotech innovation. The firm offers value-add services such as strategic guidance, operational support, and access to a robust network of industry experts to help portfolio companies achieve their growth objectives.
Dreavent Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies4
Current Portfolio Count4
Top Investment Stages
Series A3 (75.0%)
Series B1 (25.0%)
Stage Mix
Series A 75%Series B 25%
Concentration shown as share of disclosed investments by stage.